Trivalent Influenza Virus Subunit Vaccine
Our investigational trivalent influenza virus subunit vaccine is designed to provide protection against two influenza A virus subtypes (H1N1 and H3N2) and one influenza B virus (Victoria lineage), which is consistent with the coverage recommended by the World Health Organization (WHO) for the 2024-2025 influenza season in the Northern Hemisphere. This investigational trivalent influenza virus vaccine leverages the mature formulation of our approved quadrivalent influenza virus subunit vaccine, using the same antigen stock solution, with the omission of one influenza B virus subtype (Yamagata) during formulation. Based on the preclinical and clinical results of our quadrivalent influenza virus subunit vaccine, the investigational trivalent influenza virus subunit vaccines (intended for populations aged 3 years and above, and those aged 6-35 months respectively) are expected to obtain marketing approval in Q4 2025.
For all the above-mentioned products, we are seeking localized cooperation, technology transfer, and agency partnerships in overseas markets.
ONLINE
NEW PRODUCTS
Need more help?
Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.
CONTACT
- E-Mail: yue.peng@yitherbiotech.com
- Hotline: +86-021-61639751
- Address: No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai
SHARE
Copyright: Yither Biotechnology Co. Ltd Powered by:www.30.cn SEO
